Abecma Approved for Earlier Lines in R/R Multiple Myeloma

The drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.

Related Keywords

Bristol Myers Squibb ,Drug Administration ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Art Chimaeric Antigen Receptort Cell Therapy Receptors Immunoreceptors Chimaerict ,Biologic Therapy ,Iologics ,Cytokines ,Antigens ,Cancer ,